Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs

被引：23

作者：

Gowda, Lohith ^{[1
]}

Shah, Mithun ^{[2
]}

Badar, Ifra ^{[3
]}

Bashir, Qaiser ^{[3
]}

Shah, Nina ^{[4
]}

Patel, Krina ^{[5
]}

Kanagal-Shamanna, Rashmi ^{[6
]}

Mehta, Rohtesh ^{[3
]}

Weber, Donna M. ^{[5
]}

Lee, Hans C. ^{[5
]}

Manasanch, Elisabet E. ^{[5
]}

Shah, Abdul ^{[3
]}

Thomas, Sheeba K. ^{[5
]}

Parmar, Simrit ^{[3
]}

Nieto, Yago ^{[3
]}

Orlowski, Robert Z. ^{[5
]}

Champlin, Richard ^{[3
]}

Qazilbash, Muzaffar H. ^{[3
]}

机构：

[1] Yale Sch Med, Div Hematol, New Haven, CT 06511 USA

[2] Mayo Clin, Div Hematol Malignancies, Rochester, MN 55905 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplant, Houston, TX 77030 USA

[4] Univ Calif San Francisco, Div Hematol, San Francisco, CA 94143 USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA

来源：

BONE MARROW TRANSPLANTATION | 2019年 / 54卷 / 07期

关键词：

DEXAMETHASONE; LENALIDOMIDE; MYELOMA; BORTEZOMIB; CONSOLIDATION; SURVIVAL;

D O I：

10.1038/s41409-018-0392-1

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM) with poor long-term survival after cytotoxic chemotherapy. Many novel drugs have revolutionized the treatment algorithms for MM. The impact of targeted therapy, both pre- and post-autologous stem cell transplant (auto-HCT) remains an area of ongoing interest. In this study, we report outcomes post auto-HCT for pPCL and the impact of maintenance therapy posttransplant with novel agents.

引用

页码：1089 / 1093

页数：5

共 14 条

[11] Primary Plasma Cell Leukemia A Surveillance, Epidemiology, and End Results Database Analysis Between 1973 and 2004
Ramsingh, Giridharan
Mehan, Paul
Luo, Jingqin
Vij, Ravi
Morgensztern, Daniel
[J]. CANCER, 2009, 115 (24) : 5734 - 5739
[12] Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myelome
Royer, Bruno
Minvielle, Stephane
Diouf, Momar
Roussel, Murielle
Karlin, Lionel
Hulin, Cyrille
Arnulf, Bertrand
Macro, Margaret
Cailleres, Sylvie
Brion, Annie
Brechignac, Sabine
Belhadj, Karim
Chretien, Marie Lorraine
Wetterwald, Marc
Chaleteix, Carine
Tiab, Mourad
Leleu, Xavier
Frenzel, Laurent
Garderet, Laurent
Choquet, Sylvain
Fuzibet, Jean Gabriel
Dauriac, Charles
Fornecker, Luc-Matthieu
Benboubker, Lotfi
Facon, Thierry
Moreau, Philippe
Avet-Loiseau, Herve
Marolleau, Jean Pierre
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18) : 2125 - +
[13] Genetic aberrations and survival in plasma cell leukemia
Tiedemann, R. E.
Gonzalez-Paz, N.
Kyle, R. A.
Santana-Davila, R.
Price-Troska, T.
Van Wier, S. A.
Chng, W. J.
Ketterling, R. P.
Gertz, M. A.
Henderson, K.
Greipp, P. R.
Dispenzieri, A.
Lacy, M. Q.
Rajkumar, S. V.
Bergsagel, P. L.
Stewart, A. K.
Fonseca, R.
[J]. LEUKEMIA, 2008, 22 (05) : 1044 - 1052
[14] Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia
Vela-Ojeda, J
Esparza, MAGR
Rosas-Cabral, A
Padilla-González, Y
García-Chávez, J
Tripp-Villanueva, F
Sánchez-Cortés, E
Ayala-Sánchez, M
García-León, LD
Montiel-Cervantes, L
Rubio-Borja, ME
[J]. ANNALS OF HEMATOLOGY, 2002, 81 (07) : 362 - 367

← 1 2 →